CYTKbusinesswire

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Summary

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click HERE to participate. On May 1, 2025, Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months, citing additi

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 22, 2026 by businesswire